Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HUMANA INCHUM · Entity 1429 | Director | September 30, 2026 | October 02, 2026 |
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | May 26, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HUMANA INC
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,772 |
Reported balance
After 2026-09-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-30 · Grant · Acquired 238 · Balance 16,772 F3: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,800 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 24,800 F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,364 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 3,364 F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
| Humana CommonSEC Table I · non-derivative | Direct | 19,448 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 19,448 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 766 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.
F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F3: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.
Outlook Therapeutics, Inc.
Report date May 26, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 423,655 |
Reported balance
After 2026-05-26 transaction · row 1
1 source rowRow 1 · 2026-05-26 · Purchase · Acquired 400,000 · Balance 423,655 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 31, 2021 Filed Jan 4, 2022 14:38 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 212 | $465.85 | $98,760.20 |
DisclosureSEC source: 0001062993-22-000113 · form4.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679 Underlying: Humana Common · 212 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:03 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 34,425 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-21-059948 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,425 Underlying: Common Stock · 34,425 shares Expires 2031-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 13:38 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 209 | $394.00 | $82,344.96 |
DisclosureSEC source: 0000049071-21-000127 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,071 Underlying: Humana Common · 209 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 15:18 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 194 | $442.72 | $85,886.71 |
DisclosureSEC source: 0000049071-21-000103 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,862 Underlying: Humana Common · 194 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 13:53 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 199 | $422.60 | $84,097.40 |
DisclosureSEC source: 0000049071-21-000071 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,668 Underlying: Humana Common · 199 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:05 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 20,873 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-21-023278 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,873 Underlying: Common Stock · 20,873 shares Expires 2031-03-24 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:01 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-21-000005 · edgar.xml · derivative · entry 5 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403 Underlying: Humana Common · 403 shares Expires not disclosed F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2021. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 18:01 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 218 | $407.16 | $88,759.79 |
DisclosureSEC source: 0000049071-21-000005 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,469 Underlying: Humana Common · 218 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 18:01 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 227 | $407.16 | $92,424.19 |
DisclosureSEC source: 0000049071-21-000005 · edgar.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,467 Underlying: Humana Common · 227 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:42 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 116,708 | $0.51 Strike: $0.71 | $59,999.58 |
DisclosureSEC source: 0001209191-20-053866 · doc4.xml · derivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,708 Underlying: Common Stock · 116,708 shares Expires 2030-10-05 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 22:42 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 217,602 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-20-053866 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,602 Underlying: Common Stock · 217,602 shares Expires 2030-10-01 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:43 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 207 | $410.09 | $84,889.15 |
DisclosureSEC source: 0000049071-20-000125 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,251 Underlying: Humana Common · 207 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 22:07 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-043221 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 21:29 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 235 | $384.15 | $90,275.25 |
DisclosureSEC source: 0000049071-20-000098 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,044 Underlying: Humana Common · 235 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 15:40 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 239 | $308.22 | $73,663.39 |
DisclosureSEC source: 0000049071-20-000075 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,809 Underlying: Humana Common · 239 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 21:53 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-20-020510 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:58 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-20-000010 · edgar.xml · derivative · entry 5 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453 Underlying: Humana Common · 453 shares Expires not disclosed F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan. 100% of the award is vesting on 12/31/2020. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:58 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 239 | $366.09 | $87,494.32 |
DisclosureSEC source: 0000049071-20-000010 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,570 Underlying: Humana Common · 239 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:58 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 196 | $366.09 | $71,752.66 |
DisclosureSEC source: 0000049071-20-000010 · edgar.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240 Underlying: Humana Common · 196 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:07 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 60,893 | $0.99 Strike: $1.40 | $59,997.87 |
DisclosureSEC source: 0001209191-19-052708 · doc4.xml · derivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,893 Underlying: Common Stock · 60,893 shares Expires 2029-10-03 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $60,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:07 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-19-052708 · doc4.xml · derivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 14:26 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 331 | $255.05 | $84,419.90 |
DisclosureSEC source: 0000049071-19-000096 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,331 Underlying: Humana Common · 331 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 16:08 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 328 | $263.21 | $86,332.88 |
DisclosureSEC source: 0000049071-19-000074 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Humana Common · 328 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 15:12 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 329 | $263.97 | $86,844.49 |
DisclosureSEC source: 0000049071-19-000055 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,672 Underlying: Humana Common · 329 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 22:57 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 5,983 | $0.80 | $4,786.40 |
DisclosureSEC source: 0001209191-19-007844 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,947 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7679 - $0.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 1, 2019 23:25 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 8,200 | $0.77 | $6,314.00 |
DisclosureSEC source: 0001209191-19-006603 · doc4.xml · nonDerivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,964 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.745 - $0.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 23:25 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 6,300 | $0.75 | $4,725.00 |
DisclosureSEC source: 0001209191-19-006603 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,764 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.729 - $0.7695, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:25 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 4,890 | $0.72 | $3,520.80 |
DisclosureSEC source: 0001209191-19-006603 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,464 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.71 - $0.7375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 29, 2019 Filed Jan 30, 2019 00:01 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 5,400 | $0.73 | $3,942.00 |
DisclosureSEC source: 0001209191-19-005917 · doc4.xml · nonDerivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,574 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.72 - $0.7357, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 00:01 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 15,884 | $0.71 | $11,277.64 |
DisclosureSEC source: 0001209191-19-005917 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,174 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.679 - $0.7467, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 25, 2019 Filed Jan 30, 2019 00:01 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,828 | $0.69 | $7,471.32 |
DisclosureSEC source: 0001209191-19-005917 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,290 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 - $0.699, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 00:51 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 2,266 | $0.67 | $1,518.22 |
DisclosureSEC source: 0001209191-19-005247 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,462 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 - $0.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 00:51 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,749 | $0.68 | $7,309.32 |
DisclosureSEC source: 0001209191-19-005247 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,196 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6605 - $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 17, 2019 Filed Jan 18, 2019 21:51 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 2,300 | $0.69 | $1,587.00 |
DisclosureSEC source: 0001209191-19-004571 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,447 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 - $0.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 21:51 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 800 | $0.68 | $544.00 |
DisclosureSEC source: 0001209191-19-004571 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,147 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.68 - $0.687, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 22:31 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 2,266 | $0.70 | $1,586.20 |
DisclosureSEC source: 0001209191-19-003962 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,347 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.666 - $0.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 22:31 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 4,399 | $0.71 | $3,123.29 |
DisclosureSEC source: 0001209191-19-003962 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,081 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.68 - $0.7143, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 22:18 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 6,053 | $0.70 | $4,237.10 |
DisclosureSEC source: 0001209191-19-003446 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,682 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.685 - $0.7493, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 22:18 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 2,792 | $0.73 | $2,038.16 |
DisclosureSEC source: 0001209191-19-003446 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,629 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.70 - $0.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 08, 2019 Filed Jan 9, 2019 01:13 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 6,410 | $0.65 | $4,166.50 |
DisclosureSEC source: 0001209191-19-002918 · doc4.xml · nonDerivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,837 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 - $0.695, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 01:13 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 5,166 | $0.63 | $3,254.58 |
DisclosureSEC source: 0001209191-19-002918 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,427 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 - $0.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 04, 2019 Filed Jan 9, 2019 01:13 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 6,205 | $0.59 | $3,660.95 |
DisclosureSEC source: 0001209191-19-002918 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,261 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.57 - $0.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 03, 2019 Filed Jan 3, 2019 23:01 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 4,200 | $0.59 | $2,478.00 |
DisclosureSEC source: 0001209191-19-001265 · doc4.xml · nonDerivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,056 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5472 - $0.623, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:31 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-19-000004 · edgar.xml · derivative · entry 5 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 Underlying: Humana Common · 588 shares Expires not disclosed F4 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 23:01 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 1,640 | $0.59 | $967.60 |
DisclosureSEC source: 0001209191-19-001265 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,856 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.51 - $0.601, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:31 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 284 | $284.57 | $80,816.46 |
DisclosureSEC source: 0000049071-19-000004 · edgar.xml · derivative · entry 4 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,343 Underlying: Humana Common · 284 shares Expires not disclosed F3 · security: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_price: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.exercise_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). F3 · derivative.expiration_date: Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:31 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 182 | $284.57 | $51,790.83 |
DisclosureSEC source: 0000049071-19-000004 · edgar.xml · derivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044 Underlying: Humana Common · 182 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 23:01 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 11,349 | $0.59 | $6,695.91 |
DisclosureSEC source: 0001209191-19-001265 · doc4.xml · nonDerivative · entry 1 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,216 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 - $0.6031, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 28, 2018 Filed Dec 28, 2018 22:06 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 11,910 | $0.52 | $6,193.20 |
DisclosureSEC source: 0001209191-18-064336 · doc4.xml · nonDerivative · entry 3 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,867 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.45 - $0.5845, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 22:06 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 730 | $0.51 | $372.30 |
DisclosureSEC source: 0001209191-18-064336 · doc4.xml · nonDerivative · entry 2 HILZINGER KURT J · CIK 0001191504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,957 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.45 - $0.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.